Sivik Global Healthcare Has Boosted By $625,000 Its Bio (BIO) Position; Sangamo Biosciences (SGMO) Has 1.24 Sentiment

August 10, 2018 - By Carolyn Hewitt

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Sivik Global Healthcare Llc increased Bio (BIO) stake by 20% reported in 2018Q1 SEC filing. Sivik Global Healthcare Llc acquired 2,500 shares as Bio (BIO)’s stock rose 11.67%. The Sivik Global Healthcare Llc holds 15,000 shares with $3.75 million value, up from 12,500 last quarter. Bio now has $9.50B valuation. The stock increased 0.54% or $1.71 during the last trading session, reaching $318.11. About 104,757 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 30.04% since August 10, 2017 and is uptrending. It has outperformed by 17.47% the S&P500. Some Historical BIO News: 16/03/2018 – Bio-Rad Labs: KPMG Needs More Time to Ccomplete Audit, Assessment of Effectiveness of Internal Control Over Reporting; 16/03/2018 – BIO RAD LABORATORIES – CONCLUDED THAT INTERNAL CONTROL OVER FINANCIAL REPORTING WAS NOT EFFECTIVE AS OF DEC 31, 2017; 08/05/2018 – BIO-RAD 1Q EPS $21.77, EST. $1.040; 16/03/2018 – BIO RAD LABORATORIES SAYS IDENTIFIED CERTAIN INTERNAL CONTROL DEFICIENCIES ARISING FROM APRIL 2017 ERP SYSTEM & BUSINESS STRUCTURE CONVERSION; 16/03/2018 – Bio-Rad Labs Delay Prompted by Conversion to New ERP System, Business Structure for European Operations; 30/04/2018 – Bio-Rad Closes Below 50-Day Moving Average: Technicals; 22/04/2018 – DJ Bio-Rad Laboratories Inc Class B, Inst Holders, 1Q 2018 (BIO.B); 16/03/2018 – Bio-Rad Laboratories Unable to File 2017 Form 10-K by March 16 Extended Deadline; 21/04/2018 – DJ Bio-Rad Laboratories Inc Class A, Inst Holders, 1Q 2018 (BIO); 07/03/2018 NYSE HALT BIO-RAD LABS B BlOb.N ADDITIONAL INFORMATION LAST $244.70000

Sangamo Biosciences Inc (SGMO) investors sentiment decreased to 1.24 in Q1 2018. It’s down -0.16, from 1.4 in 2017Q4. The ratio dived, as 92 investment managers increased or opened new equity positions, while 74 cut down and sold holdings in Sangamo Biosciences Inc. The investment managers in our database now possess: 53.36 million shares, up from 53.22 million shares in 2017Q4. Also, the number of investment managers holding Sangamo Biosciences Inc in top ten equity positions decreased from 4 to 3 for a decrease of 1. Sold All: 12 Reduced: 62 Increased: 46 New Position: 46.

Investors sentiment decreased to 1.03 in 2018 Q1. Its down 0.10, from 1.13 in 2017Q4. It worsened, as 18 investors sold BIO shares while 101 reduced holdings. 42 funds opened positions while 81 raised stakes. 18.53 million shares or 0.19% less from 18.57 million shares in 2017Q4 were reported. Arizona State Retirement System owns 13,651 shares for 0.03% of their portfolio. Aqr Capital Mngmt Lc holds 0.01% or 34,672 shares. 224,505 were reported by Manufacturers Life Com The. Paloma Prtn invested in 0.01% or 2,722 shares. Tdam Usa stated it has 0.13% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Leavell Invest Management Incorporated has 0.05% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). First Quadrant Ltd Partnership Ca invested in 0.08% or 17,679 shares. Pointstate Capital LP reported 64,448 shares. Sector Gamma As stated it has 4.25% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Castleark Limited Liability Company has 20,055 shares. Ftb Advsrs Inc stated it has 225 shares or 0.01% of all its holdings. Moreover, Advantus Cap Management has 0.02% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 2,527 shares. Epoch Prtnrs Inc has invested 0.16% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Lpl Finance Ltd Liability Company holds 0% or 4,443 shares in its portfolio. Royal Bank Of Canada holds 783 shares.

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Seekingalpha.com which released: “Bio-Rad Laboratories (BIO) Q2 2018 Results – Earnings Call Transcript” on August 07, 2018, also Benzinga.com with their article: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” published on August 09, 2018, Benzinga.com published: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Benzinga.com and their article: “Earnings Scheduled For August 7, 2018” published on August 07, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” with publication date: August 07, 2018.

Since June 13, 2018, it had 0 insider buys, and 1 insider sale for $106,197 activity. $106,197 worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) was sold by Crowley Michael.

Among 4 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Bio-Rad Laboratories had 5 analyst reports since February 16, 2018 according to SRatingsIntel. The stock has “Hold” rating by C.L. King on Friday, February 16. CL King downgraded the shares of BIO in report on Friday, February 16 to “Neutral” rating. Wells Fargo maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Wednesday, February 28. Wells Fargo has “Outperform” rating and $280 target. The firm has “Buy” rating by Wells Fargo given on Tuesday, March 20. The firm earned “Buy” rating on Wednesday, August 8 by Jefferies.

Sivik Global Healthcare Llc decreased Becton Dickinson & Co Com Stk (NYSE:BDX) stake by 7,038 shares to 10,000 valued at $2.17M in 2018Q1. It also reduced Centene Corp Del Com Stk (NYSE:CNC) stake by 5,876 shares and now owns 64,124 shares. Bluebird Bio (NASDAQ:BLUE) was reduced too.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Seekingalpha.com which released: “Sangamo: First Look At June 2018 Results” on August 09, 2018, also Fool.com with their article: “Why Sangamo Therapeutics, Inc. Stock Is Popping Today” published on August 09, 2018, Seekingalpha.com published: “Sangamo Therapeutics to acquire TxCell” on July 23, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Streetinsider.com and their article: “Sangamo (SGMO) Reports Positive Preliminary Data from Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for …” published on August 08, 2018 as well as Benzinga.com‘s news article titled: “68 Stocks Moving In Thursday’s Mid-Day Session” with publication date: August 09, 2018.

Since January 1, 0001, it had 0 buys, and 17 selling transactions for $2.12 million activity.

Opaleye Management Inc. holds 2.91% of its portfolio in Sangamo Therapeutics, Inc. for 535,000 shares. Alexandria Capital Llc owns 881,533 shares or 2.49% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 1.56% invested in the company for 125,000 shares. The Utah-based Wasatch Advisors Inc has invested 0.91% in the stock. Eam Investors Llc, a California-based fund reported 219,415 shares.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.55 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

The stock increased 10.87% or $1.5 during the last trading session, reaching $15.3. About 7.83 million shares traded or 270.43% up from the average. Sangamo Therapeutics, Inc. (SGMO) has risen 100.00% since August 10, 2017 and is uptrending. It has outperformed by 87.43% the S&P500. Some Historical SGMO News: 03/05/2018 – SANGAMO THERAPEUTICS REPORTS SR LEADERSHIP CHANGES; 16/05/2018 – BIOVERATIV & SANGAMO REPORT FDA ACCEPTANCE OF IND APPLICATION; 16/05/2018 – BIOVERATIV, SANGAMO CITE GENE-EDITED CELL THERAPY BIVV003; 17/04/2018 – SANGAMO THERAPEUTICS INC – DATA SECURITY INCIDENT WAS LIMITED TO COMPROMISE OF SENIOR EXECUTIVE’S COMPANY EMAIL ACCOUNT FOR APPROXIMATELY 11 WEEKS; 03/05/2018 – SANGAMO: CHIEF BUSINESS OFFICER TO RESIGN EFFECTIVE JUNE 1; 17/04/2018 – SANGAMO THERAPEUTICS – INVESTIGATION DID NOT REVEAL ANY EVIDENCE THAT CO’S NETWORK OR OTHER INFORMATION TECHNOLOGY SYSTEMS WERE OTHERWISE COMPROMISED; 16/05/2018 – Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease; 04/04/2018 – Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program; 24/04/2018 – SANGAMO THERAPEUTICS TO OFFER $200.0M OF SHRS; 24/04/2018 – SANGAMO THERAPEUTICS FILES MIXED SECURITIES SHELF

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts